Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with carboplatin AUC 4 administered intravenously on Day 1 after gemcitabine administration. Refer to carboplatin prescribing information for additional information.
Dosage Modifications
Recommended gemcitabine dosage modifications for myelosuppression are described in Tables 1 and 2 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Treatment Day | Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|---|
| Day 1 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| Less than 1,500 | Or | Less than 100,000 | Delay Treatment Cycle | |
| Day 8 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| 1,000 to 1,499 | Or | 75,000 to 99,999 | 50% of full dose | |
| Less than 1,000 | Or | Less than 75,000 | Hold |
| Occurrence | Myelosuppression During Treatment Cycle | Dosage Modification |
|---|---|---|
| Initial Occurrence |
| Permanently reduce gemcitabine to 800 mg/m2 on Days 1 and 8 |
| Subsequent Occurrence | If any of the above toxicities occur after the initial dose reduction: | Permanently reduce gemcitabine to 800 mg/m2 on Day 1 only |
Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with paclitaxel 175 mg/m2 administered as a 3-hour intravenous infusion on Day 1 before gemcitabine administration. Refer to paclitaxel prescribing information for additional information.
Dosage Modifications
Recommended gemcitabine dosage modifications for myelosuppression are described in Table 3 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Treatment Day | Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|---|
| Day 1 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| Less than 1,500 | Or | Less than 100,000 | Hold | |
| Day 8 | Greater than or equal to 1,200 | And | Greater than 75,000 | None |
| 1,000 to 1,199 | Or | 50,000 to 75,000 | 75% of full dose | |
| 700 to 999 | And | Greater than or equal to 50,000 | 50% of full dose | |
| Less than 700 | Or | Less than 50,000 | Hold |
Recommended Dose and Schedule
28-day schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine administration.
21-day schedule
The recommended dosage of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine administration.
Refer to cisplatin prescribing information for additional information.
Dosage Modifications
Recommended dosage modifications for gemcitabine myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes. The recommended treatment schedule is as follows:
Dosage Modifications
Recommended dosage modifications for gemcitabine for myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|
| Greater than or equal to 1,000 | And | Greater than or equal to 100,000 | None |
| 500 to 999 | Or | 50,000 to 99,999 | 75% of full dose |
| Less than 500 | Or | Less than 50,000 | Hold |
Permanently discontinue gemcitabine for any of the following:
Withhold gemcitabine or reduce dose by 50% for other Grade 3 or 4 non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.
Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with carboplatin AUC 4 administered intravenously on Day 1 after gemcitabine administration. Refer to carboplatin prescribing information for additional information.
Dosage Modifications
Recommended gemcitabine dosage modifications for myelosuppression are described in Tables 1 and 2 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Treatment Day | Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|---|
| Day 1 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| Less than 1,500 | Or | Less than 100,000 | Delay Treatment Cycle | |
| Day 8 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| 1,000 to 1,499 | Or | 75,000 to 99,999 | 50% of full dose | |
| Less than 1,000 | Or | Less than 75,000 | Hold |
| Occurrence | Myelosuppression During Treatment Cycle | Dosage Modification |
|---|---|---|
| Initial Occurrence |
| Permanently reduce gemcitabine to 800 mg/m2 on Days 1 and 8 |
| Subsequent Occurrence | If any of the above toxicities occur after the initial dose reduction: | Permanently reduce gemcitabine to 800 mg/m2 on Day 1 only |
Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with paclitaxel 175 mg/m2 administered as a 3-hour intravenous infusion on Day 1 before gemcitabine administration. Refer to paclitaxel prescribing information for additional information.
Dosage Modifications
Recommended gemcitabine dosage modifications for myelosuppression are described in Table 3 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Treatment Day | Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|---|
| Day 1 | Greater than or equal to 1,500 | And | Greater than or equal to 100,000 | None |
| Less than 1,500 | Or | Less than 100,000 | Hold | |
| Day 8 | Greater than or equal to 1,200 | And | Greater than 75,000 | None |
| 1,000 to 1,199 | Or | 50,000 to 75,000 | 75% of full dose | |
| 700 to 999 | And | Greater than or equal to 50,000 | 50% of full dose | |
| Less than 700 | Or | Less than 50,000 | Hold |
Recommended Dose and Schedule
28-day schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine administration.
21-day schedule
The recommended dosage of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine administration.
Refer to cisplatin prescribing information for additional information.
Dosage Modifications
Recommended dosage modifications for gemcitabine myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
Recommended Dose and Schedule
The recommended dosage of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes. The recommended treatment schedule is as follows:
Dosage Modifications
Recommended dosage modifications for gemcitabine for myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].
| Absolute Neutrophil Count (× 106/L) | Platelet Count (× 106/L) | Dosage Modification | |
|---|---|---|---|
| Greater than or equal to 1,000 | And | Greater than or equal to 100,000 | None |
| 500 to 999 | Or | 50,000 to 99,999 | 75% of full dose |
| Less than 500 | Or | Less than 50,000 | Hold |
Permanently discontinue gemcitabine for any of the following:
Withhold gemcitabine or reduce dose by 50% for other Grade 3 or 4 non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.